Adjuvant chemotherapy for resected non-small-cell lung cancer: Future perspectives for clinical research

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Bonomi, Maria ^a   Pilotto, Sara ^a   Milella, Michele ^b   Massari, Francesco ^a   Cingarlini, Sara ^a   Brunelli, Matteo ^a   Chilosi, Marco ^a   Tortora, Giampaolo ^a   Bria, Emilio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

adjuvant chemotherapy; early stage lung cancer; prognostic predictive classifiers; stage Ib

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; CISPLATIN; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; MOLECULAR MARKER; NAVELBINE; PLACEBO; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL RESEARCH; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL PREDICTION; TREATMENT OUTCOME; FORECASTING; LUNG TUMOR; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FORECASTING; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 84855168417     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-115     Document Type: Review

References (86)

1. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Crino L, Weder W, van Meerbeeck J, Felip E, Ann Oncol 21 Suppl 5 &22103 115
2. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, et al. J Clin Oncol 2007 25 5506 5518 10.1200/JCO.2007.14.1226 17954710 (Pubitemid 350232227)
3. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
4. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW, Chest 2 2007 132 243S 265S 10.1378/chest.07-1379 17873172
5. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K, Chest 2 2007 132 234S 242S 10.1378/chest.07-1378 17873171
6. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995 311 899 909 7580546
7. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, et al. Lancet Oncol 2006 7 719 727 10.1016/S1470-2045(06)70804-X 16945766 (Pubitemid 44283661)
8. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al. N Engl J Med 2005 352 2589 2597 10.1056/NEJMoa043623 15972865 (Pubitemid 41007845)
9. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, et al. J Clin Oncol 28 29 34
10. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, N Engl J Med 2004 350 351 360 14736927 (Pubitemid 38101630)
11. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Pechoux C, Pirker R, Pinel MI, et al. J Clin Oncol 28 35 42
12. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, Sugarbaker DJ, Schilsky RL, Green MR, ASCO Meeting Abstracts 2004 22 7019
13. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, et al. J Clin Oncol 2008 26 5043 5051 10.1200/JCO.2008.16.4855 18809614
14. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Eur J Cardiothorac Surg 2004 26 173 182 10.1016/j.ejcts.2004.03.041 15200998 (Pubitemid 38759943)
15. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M, J Natl Cancer Inst 2003 95 1453 1461 14519751 (Pubitemid 37279330)
16. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH, N Engl J Med 2000 343 1217 1222 10.1056/NEJM200010263431703 11071672
17. Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. Douillard JY, J Clin Oncol 28 3 5
18. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al. J Clin Oncol 2008 26 3552 3559 10.1200/JCO.2007.13.9030 18506026
19. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, Sculier JP, Lung Cancer 2005 49 13 23 10.1016/j.lungcan.2005.01.002 15949586 (Pubitemid 40798089)
20. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E, Cognetti F, Giannarelli D, Lung Cancer 2009 63 50 57 10.1016/j.lungcan.2008.05.002 18565615
21. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M, J Clin Oncol 2004 22 3860 3867 10.1200/JCO.2004.01.153 15326194 (Pubitemid 41079866)
22. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. Sedrakyan A, Van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T, J Thorac Cardiovasc Surg 2004 128 414 419 10.1016/j.jtcvs.2004.04.027 15354101 (Pubitemid 39194698)
23. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, et al. Lancet 2010 375 1267 1277 20338627
24. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Banna GL, Di Maio M, Follador A, Collova E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, et al. Lung Cancer 73 78 88
25. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ, J Clin Oncol 28 3472 3478
26. Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study. Cuffe S, Booth CM, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ, Shepherd FA, ASCO Meeting Abstracts 29 7012
27. Platinum-based adjuvant chemotherapy (ACT) in elderly patients with non-small cell lung cancer (NSCLC) in the SEER-Medicare database: Comparison between carboplatin- and cisplatin-based regimens. Gu F, Strauss GM, Wisnivesky JP, ASCO Meeting Abstracts 29 7014
28. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. Wisnivesky JP, Smith CB, Packer S, Strauss GM, Lurslurchachai L, Federman A, Halm EA, BMJ 343 4013
29. Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. Zornosa C, Mamet R, Reid ME, Ettinger DS, Otterson GA, Rabin MS, Hayman J, Niland JC, Pisters K, Committee NOODN-SCLCD-SE, ASCO Meeting Abstracts 28 7017
30. Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. Miksad RA, Gonen M, Lynch TJ, Roberts TG Jr, J Clin Oncol 2009 27 2245 2252 10.1200/JCO.2008.16.2586 19307513
31. Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633. Strauss GM, Wang XF, Maddaus M, Johnstone D, Johnson E, Harpole D, Gillenwater HH, Gu L, Sugarbaker D, Green MR, et al. ASCO Meeting Abstracts 29 7015
32. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, N Engl J Med 2004 350 1713 1721 10.1056/NEJMoa032792 15102997 (Pubitemid 38501140)
33. Optimal adjuvant therapy for non-small cell lung cancer - how to handle stage I disease. Wakelee H, Dubey S, Gandara D, Oncologist 2007 12 331 337 10.1634/theoncologist.12-3-331 17405898 (Pubitemid 46556800)
34. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallieres E, Goldstraw P, J Thorac Oncol 2007 2 593 602 10.1097/JTO.0b013e31807a2f81 17607114 (Pubitemid 47171780)
35. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, J Thorac Oncol 2007 2 706 714 10.1097/JTO.0b013e31812f3c1a 17762336 (Pubitemid 47357522)
36. Significance of the presence of microscopic vascular invasion after complete resection of Stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-Size categories: did the 2009 7th edition of the TNM staging system miss something? Ruffini E, Asioli S, Filosso PL, Buffoni L, Bruna MC, Mossetti C, Solidoro P, Oliaro A, J Thorac Oncol 6 319 326
37. Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K, Chest 139 855 861
38. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998 352 257 263 9690404
39. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005 D002142
40. What now for postoperative radiotherapy for lung cancer? Munro AJ, Lancet 1998 352 250 251 10.1016/S0140-6736(98)22030-7 9690399 (Pubitemid 28340137)
41. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA, Int J Radiat Oncol Biol Phys 2008 72 695 701 10.1016/j.ijrobp.2008.01.044 18439766
42. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Lally BE, Detterbeck FC, Geiger AM, Thomas CR Jr, Machtay M, Miller AA, Wilson LD, Oaks TE, Petty WJ, Robbins ME, Blackstock AW, Cancer 2007 110 911 917 10.1002/cncr.22845 17620279 (Pubitemid 47257671)
43. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved. Matsuguma H, Nakahara R, Ishikawa Y, Suzuki H, Inoue K, Katano S, Yokoi K, Interact Cardiovasc Thorac Surg 2008 7 573 577 10.1510/icvts.2007.174342 18413349
44. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Trastek VF, Pairolero PC, Allen MS, Lange CM, Li H, Ann Thorac Surg 1997 64 1402 1407 discussion 1407-1408 10.1016/S0003-4975(97)00908-9 9386711
45. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA, J Clin Oncol 2007 25 1553 1561 10.1200/JCO.2006.09.5570 17442999 (Pubitemid 46733082)
46. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti GV, Douillard JY, et al. J Clin Oncol 2008 26 3573 3581 10.1200/JCO.2008.16.2727 18640938
47. Chemotherapy in elderly patients with resected stage II-IIIA lung cancer. Fervers B, BMJ 343 4104
48. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L, Lung Cancer 2005 47 385 394 10.1016/j.lungcan.2004.08.016 15713522 (Pubitemid 40248743)
49. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, Sugarbaker DJ, Schilsky RA, Vokes EE, Green MR, The Calgb RTOG, ASCO Meeting Abstracts 2006 24 7007
50. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? Besse B, Le Chevalier T, J Clin Oncol 2008 26 5014 5017 10.1200/JCO.2008.18.1081 18809602
51. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. Custodio AB, Gonzalez-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, Manzano A, Diaz-Rubio E, J Thorac Oncol 2009 4 891 910 10.1097/JTO.0b013e3181a4b8fb 19433989
52. Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. Xie Y, Minna JD, J Clin Oncol 28 4404 4407
53. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, J Thorac Oncol 2008 3 457 466 10.1097/JTO.0b013e31816de2b8 18448996 (Pubitemid 351630271)
54. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Bria E, Milella M, Sperduti I, Alessandrini G, Visca P, Corzani F, Giannarelli D, Cerasoli V, Cuppone F, Cecere FL, et al. Lung Cancer 2009 66 365 371 10.1016/j.lungcan.2009.02.024 19327866
55. Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer. Jonnalagadda S, Arcinega J, Smith C, Wisnivesky JP, Cancer
56. The Number of Lymph Node Metastases as a Prognostic Factor in Patients With N1 Non-small Cell Lung Cancer. Jonnalagadda S, Smith C, Mhango G, Wisnivesky JP, Chest 140 433 440
57. A five-gene signature and clinical outcome in non-small-cell lung cancer. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al. N Engl J Med 2007 356 11 20 10.1056/NEJMoa060096 17202451 (Pubitemid 46041749)
58. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, et al. Clin Cancer Res 17 1490 1501
59. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S, Cancer Res 70 36 45
60. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, et al. N Engl J Med 2006 355 570 580 10.1056/NEJMoa060467 16899777 (Pubitemid 44200650)
61. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, et al. Clin Cancer Res 2008 14 4794 4799 10.1158/1078-0432.CCR-08-0576 18676750
62. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T, J Natl Cancer Inst 2007 99 858 867 10.1093/jnci/djk197 17551146
63. Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer? Konopa K, Ann Oncol 21 Suppl 7 &22ii199 202
64. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al. Nat Med 2008 14 822 827 10.1038/nm.1790 18641660
65. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? Subramanian J, Simon R, J Natl Cancer Inst 102 464 474
66. Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, et al. N Engl J Med 364 1176
67. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Pao W, Chmielecki J, Nat Rev Cancer 10 760 774
68. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. N Engl J Med 2006 355 983 991 10.1056/NEJMoa060570 16957145 (Pubitemid 44343542)
69. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, Andre F, Stahel R, Pignon JP, et al. J Clin Oncol 2007 25 2735 2740 10.1200/JCO.2006.08.2867 17602078 (Pubitemid 47123181)
70. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V, Popper H, Pirker R, Bertrand P, Dunant A, et al. Clin Cancer Res 16 1206 1215
71. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andre F, Brambilla E, Stahel R, Pignon JP, Soria JC, et al. Clin Cancer Res 2007 13 3892 3898 10.1158/1078-0432.CCR-06-2446 17606722 (Pubitemid 47037596)
72. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, et al. Cancer Res 70 8288 8298
73. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, et al. J Clin Oncol 2007 25 5240 5247 10.1200/JCO.2007.12.6953 18024870 (Pubitemid 350232256)
74. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al. J Clin Oncol 28 4417 4424
75. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C, Mol Cancer Ther 2005 4 2001 2007 10.1158/1535-7163.MCT-05-0244 16373715 (Pubitemid 43056983)
76. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, et al. Clin Cancer Res 2007 13 994 999 10.1158/1078-0432.CCR-06-1503 17289895 (Pubitemid 46340378)
77. LACE-BIO pooled analysis of the prognostic and predictive value of p53 mutations and expression by immunoistochemistry (IHC) in patients with resected non-small cell lung cancer (NSCLC)- Abs 389P. Graziano SL, Paris E, Ma X, Pignon J, Hainaut P, Taron M, Tsao MS, Kratzke R, Brambilla E, Soria JC, ESMO Meeting Abstracts 2010 21
78. LACE-BIO pooled analysis of the prognostic and predictive value of KRAS mutation in completely resected non small cell lung cancer (NSCLC). Abs 156O. Tsao MS, Hainaut P, Bourredjem A, Janne PA, Pignon J, Douillard J, Soria JC, Seymour L, Shepherd F, ESMO Meeting Abstracts 2010 21
79. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G, N Engl J Med 2007 356 800 808 10.1056/NEJMoa065411 17314339 (Pubitemid 46294612)
80. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, et al. PLoS One 2007 2 1129 10.1371/journal.pone.0001129 17987116 (Pubitemid 351594028)
81. Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model. Bria E, Mottolese M, Sperduti I, Visca P, Antoniani B, Facciolo F, Di Modugno F, Cognetti F, Nistico P, Milella M, ASCO Meeting Abstracts 28 7027
82. Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. D'Angelo SP, Janjigian YY, Kris MG, Pao W, Riely GJ, Marks J, Sima C, Dycoco J, Park BJ, Azzoli CG, ASCO Meeting Abstracts 28 7011
83. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K, Lancet 2005 366 1527 1537 10.1016/S0140-6736(05)67625-8 16257339 (Pubitemid 41540110)
84. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR, J Clin Oncol 2008 26 2450 2456 10.1200/JCO.2007.14.4824 18378568
85. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. Goss GD, Lorimer I, Tsao MS, O'Callaghan CJ, Ding K, Masters GA, Roberts P, Jett JR, Edelman MJ, Shepherd FA, ASCO Meeting Abstracts 28 BA7005
86. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG, J Thorac Oncol 6 569 575